Exhibit 99.1

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED

MARCH 31, 2022

(UNAUDITED)

 

1

 

 

INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2022

(UNAUDITED)

 

Item

 

Page

Consolidated Balance Sheets

 

2

Consolidated Statements of Operations and Comprehensive Loss

 

3

Consolidated Statements of Changes in Equity

 

4-5

Consolidated Statements of Cash Flows

 

6

Notes to Condensed Consolidated Interim Financial Statements

 

7-19

1

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

Consolidated Balance Sheets      
(in thousands, except share data)      
       
   March 31, 2022   December 31, 2021 
ASSETS      
Current assets      
Cash and cash equivalents $293,649  $243,179 
Short-term deposits  182,000   259,000 
Accounts receivable, net of allowance for credit losses of $0.7 million and $0.5 million as of March 31, 2022 and December 31, 2021, respectively  136,444   129,382 
Inventories  143,116   129,147 
Prepaid expenses  8,477   6,871 
Other current assets  24,185   33,123 
Total current assets  787,871   800,702 
Non-current assets      
Property, plant and equipment, net  200,627   203,295 
Goodwill  65,089   65,144 
Other intangible assets, net  143,317   152,244 
Operating lease right-of-use assets  14,162   14,651 
Long-term investments  28,667   28,667 
Other non-current assets  16,651   12,519 
Total non-current assets  468,513   476,520 
      
Total assets $1,256,384  $1,277,222 
      
LIABILITIES AND EQUITY      
Current liabilities      
Accounts payable  $59,010  $51,976 
Accrued expenses and other current liabilities  44,198   55,358 
Accrued compensation and related benefits   38,341   44,684 
Deferred revenues - short term  52,337   51,174 
Operating lease liabilities - short term  7,158   7,276 
Total current liabilities  201,044   210,468 
Non-current liabilities      
Deferred revenues - long term  22,026   21,133 
Deferred income taxes - long term  6,258   7,341 
Operating lease liabilities - long term  7,220   7,693 
Contingent consideration - long term  53,648   53,478 
Other non-current liabilities  23,487   21,095 
Total non-current liabilities  112,639   110,740 
      
Total liabilities $313,683  $321,208 
      
Contingencies (see note 12)  
   
 
      
Equity      
Ordinary shares, NIS 0.01 nominal value, authorized 180,000 thousand shares; 66,408 thousand shares and 65,677 thousand shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively $185  $182 
Additional paid-in capital  3,021,166   3,012,481 
Accumulated other comprehensive loss  (9,824  (8,771
Accumulated deficit  (2,068,826  (2,047,878
Total equity  942,701   956,014 
      
Total liabilities and equity $1,256,384  $1,277,222 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

2

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

Consolidated Statements of Operations and Comprehensive Loss    
(in thousands, except per share data)
Three Months Ended March 31,
 2022   2021 
    
Revenues     
Products$113,073  $90,324 
Services 50,356   43,865 
 163,429   134,189 
Cost of revenues     
Products 59,373   46,920 
Services 34,379   31,692 
  93,752   78,612 
     
Gross profit 69,677   55,577 
    
Operating expenses     
Research and development, net 23,998   20,601 
Selling, general and administrative 65,263   53,334 
 89,261   73,935 
     
Operating loss (19,584  (18,358
     
Financial expenses, net (1,362  (377
     
Loss before income taxes (20,946  (18,735
     
Income tax benefit 73   942 
Share in losses of associated companies (75  (1,118
     
Net loss$(20,948 $(18,911
     
Net loss per share - basic and diluted$(0.32 $(0.32
Weighted average ordinary shares outstanding - basic and diluted 65,721   58,616 
     
Comprehensive loss     
Net loss (20,948  (18,911
Other comprehensive income (loss), net of tax:     
Foreign currency translation adjustments (702  (961
Unrealized gains on derivatives designated as cash flow hedges (351  2,173 
Other comprehensive income (loss), net of tax (1,053  1,212 
Comprehensive loss$(22,001 $(17,699
 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

3

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

Consolidated Statements of Changes in Equity      
(in thousands )            
Three Months Ended March 31, 2022      
         Accumulated  
     Additional   Other  
 Ordinary SharesPaid-InAccumulated ComprehensiveTotal
 Number of shares Par ValueCapitaldeficitLossEquity
Balance as of December 31, 2021 65,677 $182 $3,012,481 $(2,047,878$(8,771$956,014 
Issuance of shares in connection with stock-based compensation plans 731  3  152  
-
  
-
  155 
Stock-based compensation -  
-
  8,533  
-
  
-
  8,533 
Comprehensive loss -  
-
  
-
  (20,948 (1,053 (22,001
Balance as of March 31, 2022 66,408 $185 $3,021,166 $(2,068,826$(9,824$942,701 
 
 The accompanying notes are an integral part of these condensed consolidated interim financial statements.
 
4

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

Consolidated Statements of Changes in Equity    
(in thousands )           
Three Months Ended March 31, 2021    
          Accumulated  
      Additional    Other 
  Ordinary Shares Paid-In Accumulated  Comprehensive Total
  Number of shares  Par Value Capital deficit Loss Equity
Balance as of December 31, 2020  56,617  $155  $2,753,955  $(1,985,896 $(8,846 $759,368 
Issuance of shares in connection with stock-based compensation plans  670  2  2,881  
-
  
-
  2,883 
Stock-based compensation  -  
-
  7,205  
-
  
-
   7,205 
Public offering of ordinary shares, net  7,931   24   218,851   
-
   
-
   218,875 
Deferred tax assets in connection with public offering expenses  -   
-
   1,156   
-
   
-
   1,156 
Comprehensive income (loss)  -   
-
   
-
   (18,911  1,212   (17,699
Balance as of March 31, 2021  65,218  $181  $2,984,048  $(2,004,807 $(7,634 $971,788 

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

 

5

STRATASYS LTD.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

(Unaudited)

Consolidated Statements of Cash Flows     
(in thousands)  Three Months Ended March 31,
   2022   2021 
Cash flows from operating activities     
Net loss  $(20,948 $(18,911
      
Adjustments to reconcile net loss to net cash provided by operating activities:     
Depreciation and amortization   15,290   13,802 
Stock-based compensation   8,533   7,205 
Foreign currency transaction loss   2,792   4,181 
Share in losses of associated companies   75   1,118 
Revaluation of investments   1,061   (3,670
Other non-cash items, net   83   193 
      
Change in cash attributable to changes in operating assets and liabilities:     
Accounts receivable, net   (7,950  2,620 
Inventories   (14,775  7,046 
Other current assets and prepaid expenses   7,386   (3,775
Other non-current assets   (85  1,595 
Accounts payable   7,194   10,197 
Other current liabilities   (16,037  6,453 
Deferred revenues   2,522   (433
Deferred income taxes, net and uncertain tax positions   (381  (1,774
Other non-current liabilities   (823  (3,096
Net cash provided by (used in) operating activities   (16,063  22,751 
      
Cash flows from investing activities     
Cash paid for acquisitions, net of cash acquired   
-
   (6,356
Purchase of property and equipment   (3,741  (4,012
Investments in short-term bank deposits   (40,000  (109,000
Proceeds from short-term bank deposits   117,000   27,000 
Purchase of intangible assets   (444  (278
Other investing activities   (47  (98
Investments in unconsolidated entities   (5,030  
-
 
Net cash provided by (used in) investing activities   67,738   (92,744
      
Cash flows from financing activities     
Proceeds from public offering, net of issuance costs   
-
   218,875 
Proceeds from exercise of stock options   155   2,883 
Other financing activities   866   407 
Net cash provided by financing activities   1,021   222,165 
      
Effect of exchange rate changes on cash, cash equivalents and restricted cash   (2,228  (2,872
      
Net change in cash, cash equivalents and restricted cash   50,468   149,300 
Cash, cash equivalents and restricted cash, beginning of period   243,293   272,216 
      
Cash, cash equivalents and restricted cash, end of period  $293,761  $421,516 
      
Supplemental disclosures of cash flow information:     
Transfer of inventory to fixed assets   188   884 
Transfer of fixed assets to inventory   120   210 
      
     
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:     
Cash and cash equivalents   293,649   421,398 
Restricted cash included in other current assets   112   118 
Total cash, cash equivalents and restricted cash shown in the consolidated statement of cash flows  $293,761  $421,516 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

6

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 1. Business Description and Basis of Presentation

Stratasys Ltd. (collectively with its subsidiaries, the “Company” or “Stratasys”) is a global leader in connected, polymer-based 3D printing solutions, across the entire manufacturing value chain. The Company leverages its competitive advantages, which include a broad set of best-in-class 3D printing platforms, software, a materials and technology partner ecosystem, innovative leadership, and global GTM infrastructure, in order to position itself to capture share in a significant and growing global marketplace, with a focus on manufacturing. The Company’s approximately 1,700 granted and pending additive technology patents to date have been used to create models, prototypes, manufacturing tools, and production parts for a multitude of industries including aerospace, automotive, transportation, healthcare, consumer products, dental, medical, and education. Stratasys’ products and comprehensive solutions improve product quality, development time, cost, and time-to-market. The Company’s 3D ecosystem of solutions and expertise includes 3D printers, materials, software, expert services, and on-demand parts production.

The condensed consolidated interim financial information herein is unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in the opinion of management, necessary for a fair statement of results for the interim period. The condensed consolidated interim financial statements include the accounts of Stratasys Ltd. and its subsidiaries. All intercompany accounts and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated in consolidation.

The Company’s financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), which require the Company to make estimates based on assumptions about current and, for some estimates, future economic and market conditions which affect reported amounts and related disclosures in its financial statements. Although the Company’s current estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from the Company’s expectations, which could materially affect its results of operations and financial position.
In particular, a number of estimates have been and will continue to be affected by the COVID-19 pandemic and/or by macroeconomic conditions that have been triggered as a result of steps taken by governments to counter-act the pandemic. The global economic environment that has set in after the most severe period of the COVID-19 pandemic has passed - assuming that it has passed - remains uncertain, rapidly changing and difficult to predict. The magnitude and duration of, as well as the consequences of, global macroeconomic trends triggered, in large part, by the recovery from the pandemic, such as inflationary pressures and supply chain problems, remain ambiguous currently. As a result, the accounting estimates and assumptions may change over time in response to post-COVID-19 trends. Such changes could have an additional impact on the Company’s long-lived asset and intangible asset valuation; inventory valuation; assessment of the annual effective tax rate; and the allowance for expected credit losses and bad debt.
The results of operations for the three months ended March 31, 2022 are not indicative of results that could be expected for the entire fiscal year. Certain financial information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. The reader is referred to the audited consolidated financial statements and notes thereto for the year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 24, 2022 as part of the Company’s Annual Report on Form 20-F for such year.

 

Note 2. New Accounting Pronouncements

Accounting Pronouncements Adopted in 2022
     In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The amendments to this guidance are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted this guidance effective January 1, 2022, with no material impact on its consolidated financial statements.
 
Recently issued accounting pronouncements, not yet adopted
     In October 2021, the FASB issued ASU 2021-08 “Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers. The guidance will result in the acquirer recognizing contract assets and contract liabilities at the same amounts recorded by the acquiree. The guidance should be applied prospectively to acquisitions occurring on or after the effective date. The guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption is permitted, including in interim periods, for any financial statements that have not yet been issued.  The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements.
 
7


STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
 
 Note 3. Certain Transactions
 
 
Investment in Xaar 3D Ltd. ("Xaar 3D")
During the fourth quarter of 2019, the Company entered into an agreement with Xaar plc (“Xaar”) to purchase additional shares of Xaar 3D that was to increase its stake from 15 to 45 percent, with Xaar retaining the remaining 55 percent. Xaar and Stratasys had announced the formation of Xaar 3D Ltd in July 2018 for the purpose of developing Powder Bed Fusion (“PBF”) additive manufacturing solutions that Stratasys can bring to the market. In addition, the agreement included an option for Stratasys to acquire the remaining shares of Xaar 3D.
Following the additional investment, the Company considered the FASB guidance in accordance with ASC Topic 810 “Consolidation” regarding the propriety of implementing consolidation, for both the variable interest entity and voting model, or equity method accounting. The Company concluded that it should continue accounting for the investment according to the equity method, as it had retained the ability to exercise significant influence but did not control Xaar 3D. For its additional interest in Xaar 3D, the Company paid approximately $15.7 million.
The investment was presented under other non-current assets in the Company’s consolidated balance sheets.
 
    On November 1, 2021 (the “Xaar 3D transaction date”) , the Company acquired the remaining 55% share of Xaar 3D, for an aggregate purchase price of $29.3 million. The Company paid cash upon closing and it is obligated to make additional earn-out payments and payments of royalties on products and services sales for up to 15 years.
 
    The Xaar 3D transaction is reflected in accordance with ASC Topic 805, “Business Combinations”, using the acquisition method of accounting, with the Company as the acquirer. The Company accounted for the acquisition of the remaining equity of Xaar 3D as a step acquisition, which required re-measurement of the Company’s previous ownership interest to fair value prior to completing purchase accounting. Using step acquisition accounting, the Company increased the value of its previously-held equity investment to its fair value of $23.8 million, which resulted in a gain of approximately $14.4 million, recorded in the consolidated statements of operations in the fourth quarter of 2021. The acquisition of the remaining equity interest also resulted in the recognition of a previously unrealized foreign currency gain of $0.6 million, which was reclassified from accumulated other comprehensive income (OCI). The fair value of the previously held equity method investment was determined based upon a valuation of the acquired business, as of the date of acquisition, as detailed below.
 
The following table summarizes the fair value of the consideration transferred to Xaar 3D’s stockholders for the Xaar 3D transaction:
 
 U.S. $ in thousands
Cash payments$13,967 
Contingent consideration at estimated fair value 15,314 
Total consideration for 55% holding 29,281 
  
Fair value of 45% holding 23,775 
  
Total consideration$53,056 

 
     In accordance with ASC Topic 805, the estimated contingent consideration as of the Xaar 3D transaction date was included in the purchase price. The total contingent payments could reach a maximum aggregate amount of up to $21 million. The estimated fair value of the contingent consideration is based on management’s assessment of whether, and at what level, the financial metrics will be achieved, and the present value factors associated with the timing of the payments. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the fair value of contingent consideration will be recorded in operating expenses.
 
8

STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
 
   The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the Xaar 3D transaction date. The estimated fair values are preliminary and based on the information that was available as of November 1, 2021. Thus, the measurements of fair value that are reflected are subject to changes, and such changes could be significant. The preliminary allocation of the purchase price to assets acquired and liabilities assumed is as follows:
 
 
 
 Allocation of Purchase Price
 (U.S. $ in thousands)
Cash and cash equivalents$82 
Goodwill 25,375 
Intangible assets 45,000 
Other assets 5,280 
Total assets acquired 75,737 
  
Net deferred tax liabilities 1,736 
Other labilities 20,945 
Total liabilities assumed 22,681 
  
Net assets acquired$53,056 
 
   RPS acquisition
 
     On February 16, 2021 the Company acquired RP Support Limited (“RPS”), a provider of industrial stereolithography 3D printers and solutions. In exchange for 100% of the outstanding shares of RPS, the Company paid cash upon closing and is obligated to make additional payments (in cash), subject to performance-based criteria, via earn-out payments over two years.
 
   Marketable equity investment
 
     The Company recognized a loss of $1.1 million for revaluation of an equity investment in the first quarter of 2022 and a gain of $3.7 million in the first quarter of 2021. The entity in which the Company invested has become public during the first quarter of 2021 and accordingly the investment is treated as a marketable equity investment. Prior to the first quarter of 2021, the investment was treated as a non-marketable equity investment without readily determinable fair value. 
 
    MakerBot and Ultimaker transaction 
 
    On May 12, 2022, the company announced the creation of a new company (“the combined company”) comprised of MakerBot and Ultimaker. Under the terms of the agreement, Stratasys will contribute MakerBot assets, invest $47 million and own 45.6% of the combined company. While NPM Capital will contribute Ultimaker assets, invest $15.4 million, and own 54.4% of the combined company. The transaction expected to close within few months.
    The Company will account for the investment, in the combined company according to the equity method in accordance with ASC topic 323, as it has retained the ability to exercise significant influence but does not control the new entity.
 
 
9

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 4. Revenues

 

Disaggregation of Revenues

The following table presents the Company’s revenues disaggregated by geographical region (based on the Company’s customers’ locations) and revenue type for the three months ended March 31, 2022 and 2021:

 

 

 Three months ended March 31,
  2022  2021
 (U.S. $ in thousands)
Americas    
Systems$28,982  $21,357 
Consumables 31,354   28,211 
Service 38,231   32,545 
Total Americas 98,567   82,113 
     
EMEA    
Systems 15,076   9,698 
Consumables 17,825   12,803 
Service 7,153   6,417 
Total EMEA 40,055   28,918 
     
Asia Pacific    
Systems 10,458   8,825 
Consumables 9,377   9,430 
Service 4,972   4,903 
Total Asia Pacific 24,807   23,158 
     
Total Revenues$163,429  $134,189 

The following table presents the Company’s revenues disaggregated based on the timing of revenue recognition (at a specific point in time or over the course of time) for the three months ended March 31, 2022 and 2021:

 

 Three months ended March 31,
  2022  2021 
 (U.S. $ in thousands)
Revenues recognized in point in time from:   
Products$113,073 $90,324 
Services 12,492  10,601 
Total revenues recognized in point in time 125,565  100,925 
    
    
Revenues recognized over time from:   
Services 37,864  33,264 
Total revenues recognized over time 37,864  33,264 
    
Total Revenues$163,429 $134,189 
10

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Contract Assets and Contract Liabilities

Contract assets are recorded when the Company’s right to consideration is conditional on constraints other than the passage of time. The Company had no material contract assets as of March 31, 2022 and December 31, 2021.
Contract liabilities include advance payments and billings in excess of revenue recognized, which are primarily related to advanced billings for service type warranty. Contract liabilities are presented under deferred revenue. The Company’s deferred revenue as of March 31, 2022 and December 31, 2021 was as follows:

 

 

  March 31,December 31,
   2022   2021 
  U.S. $ in thousands
Deferred revenue* $74,363  $72,307 

*Includes $22.0 million and $21.1 million under long term deferred revenue in the Company's consolidated balance sheets as of March 31, 2022 and December 31, 2021, respectively.

Revenue recognized in 2022 that was included in deferred revenue balance as of December 31, 2021 was $17.6 million for the three months ended March 31, 2022.

Remaining Performance Obligations

Remaining Performance Obligations (RPO) represent contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of March 31, 2022, the total RPO amounted to $126 million. The Company expects to recognize $96.3 million of this RPO during the next 12 months, $18.3 million over the subsequent 12 months and the remaining $11.4 million thereafter.

Incremental Costs of Obtaining a Contract

Sales commissions earned mainly by the Company’s sales agents are considered incremental costs of obtaining a contract with a customer, as the Company expects the benefit of those commissions to be longer than one year. The majority of the sales commissions are not subject to capitalization, as the commission expense is recognized as the related revenue is recognized. Sales commissions for initial contracts related to the service type warranty are deferred and then amortized on a straight-line basis over the expected customer relationship period if the Company expects to recover those costs. Amortization expense is included in selling, general and administrative expenses in the consolidated statements of operations. As of March 31, 2022 and December 31, 2021, the deferred commissions amounted to $7.9 million and $7.4 million, respectively.

 

11

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 5. Inventories

Inventories consisted of the following:

 

  March 31, December 31,
  2022 2021
  U.S. $ in thousands
Finished goods $65,270  $58,784 
Work-in-process  4,461   4,360 
Raw materials  73,385   66,003 
 $143,116  $129,147 

 

Note 6. Goodwill and Other Intangible Assets

      Goodwill

Changes in the carrying amount of the Company’s goodwill during the three months ended March 31, 2022 were as follows:

 

  U.S. $ in thousands
   
Goodwill as of January 1, 2022 $65,144 
Foreign currency translation adjustments   (55) 
Goodwill as of March 31, 2022 $65,089 
       
12

STRATASYS LTD.
NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
   

      Other Intangible Assets

Other intangible assets consisted of the following:

 

  March 31, 2022 December 31, 2021
   Carrying Amount,      Net   Carrying Amount,   Net
    Net of   Accumulated   Book   Net of Accumulated Book
    Impairment    Amortization   Value   Impairment  Amortization Value
  U.S. $ in thousands
Developed technology $406,371  $(285,972 $120,399  $406,578  $(279,037 $127,541 
Patents  16,655   (8,823  7,832   16,220   (8,503  7,717 
Trademarks and trade names  26,062   (22,522  3,540   26,055   (22,241  3,814 
Customer relationships  100,619   (89,073  11,546   100,731   (87,559  13,172 
Capitalized software development costs  7,066   (7,066  
-
   7,410   (7,410  - 
  $556,773  $(413,456 $143,317  $556,994 $(404,750$152,244 

Amortization expenses relating to intangible assets for the three-month period ended March 31, 2022 and 2021 were approximately $9.2 million and $7.5 million, respectively.

 

As of March 31, 2022, the estimated amortization expenses relating to intangible assets for each of the following future periods were as follows:

  Estimated
  amortization expense
  (U.S. $ in thousands)
Remaining 9 months of 2022 $27,706 
2023  22,164 
2024  18,256 
2025  15,662 
2026  15,591 
2027 and thereafter  43,938 
Total $143,317 

 

13

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

Note 7. Net Loss Per Share

The following table presents the numerator and denominator of the basic and diluted net loss per share computations for the three months ended March 31, 2022 and 2021:

  Three Months Ended March 31,
   2022   2021 
  (In thousands, except per share amounts)
Numerator:      
Net loss for basic and diluted loss per share $(20,948 $(18,911
    
Denominator:       
Weighted average shares - for basic and diluted net loss per share  65,721   58,616 
      
Net loss per share      
Basic and diluted $(0.32 $(0.32

The computation of diluted net loss per share excluded share awards of 5.4 million shares for the three months ended March 31, 2022 and 2021, because the inclusion of those shares would have had an anti-dilutive effect on the diluted net loss per share.

 

Note 8. Income Taxes

 
        The Company had income tax benefit of $0.1 million for the three-month period ended March 31, 2022 compared to income tax benefit of $0.9 million for the three-month period ended March 31, 2021. The Company’s effective tax rate as of March 31, 2022 was primarily impacted by the geographic mix of its earnings and losses, as well as its valuation allowance. 

 

14

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 9. Fair Value Measurements

The following table summarizes the Company’s financial assets and liabilities that are carried at fair value on a recurring basis, in its consolidated balance sheets:

 March 31, 2022 December 31, 2021
 Level 2 Level 3 Level 2 Level 3
 (U.S. $ in thousands)
Assets:       
Foreign exchange forward contracts not designated as hedging instruments$41   
-
  $82   
-
 
Foreign exchange forward contracts designated as hedging instruments 981   
-
   910   
-
 
        
Liabilities:       
Foreign exchange forward contracts not designated as hedging instruments (90  
-
   (89  
-
 
Foreign exchange forward contracts designated as hedging instruments (32  
-
   (60  
-
 
Total contingent consideration* 
-
   56,050   
-
   55,919 
 $900  $56,050  $843  $55,919 

  *Includes $2.4 million under Accrued expenses and other current liabilities in the Company's consolidated balance sheets as of March 31, 2022 and December 31, 2021.

The Company’s foreign exchange forward contracts are classified as Level 2, as they are not actively traded and are valued using pricing models that use observable market inputs, including interest rate curves and both forward and spot prices for currencies (Level 2 inputs).

Contingent consideration represents liabilities recorded at fair value in connection with acquisitions, and thus represents a Level 3 measurement within the fair value hierarchy (refer to Note 3).

Other financial instruments consist mainly of cash and cash equivalents, short-term deposits, current and non-current receivables, accounts payable and other current liabilities. The fair value of these financial instruments approximates their carrying values.

 

15

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 10. Derivative instruments and hedging activities

Since the Company conducts its operations globally, it is exposed to global market risks and to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign currency exchange rates. The Company enters into transactions involving foreign currency exchange derivative financial instruments. The Company manages its foreign currency exposures on a consolidated basis, which allows the Company to net exposures and take advantage of any natural hedging. The transactions are designed to manage the Company’s net exposure to foreign currency exchange rates and to reduce the volatility of earnings and cash flows associated with changes in foreign currency exchange rates. The Company does not enter into derivative transactions for trading purposes.

The Company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities and forecasted transactions denominated in the New Israeli Shekel (“NIS”), Euro, GBP, Korean Won, Chinese Yuan and the Japanese Yen. The gains and losses on the hedging instruments partially offset losses and gains on the hedged items. Financial markets and currency volatility may limit the Company’s ability to hedge these exposures. These contracts mature through December 2022.

The following table summarizes the consolidated balance sheets classification and fair values of the Company’s derivative instruments:

 

    Fair Value Notional Amount
    March 31, December 31, March 31, December 31,
  Balance sheet location 2022 2021 2022 2021
    U.S. $ in thousands
Assets derivatives -Foreign exchange contracts, not designated as hedging instruments Other current assets $41  $82  $15,343  $12,380 
Assets derivatives -Foreign exchange contracts, designated as cash flow hedge Other current assets  981   910   72,758   60,408 
Liability derivatives -Foreign exchange contracts, not designated as hedging instruments Accrued expenses and other current liabilities  (90  (89  26,852   33,047 
Liability derivatives -Foreign exchange contracts, designated as hedging instruments Accrued expenses and other current liabilities  (32  (60  10,355   26,320 
    $900  $843  $125,309  $132,155 

Foreign exchange contracts not designated as hedging instruments

As of March 31, 2022, the notional amounts of the Company’s outstanding exchange forward contracts, not designated as hedging instruments, were $42.2 million, and were used to reduce foreign currency exposures. With respect to such derivatives, gains of $0.7 million and of $2.2 million were recognized under financial income, net for the three-month period ended March 31, 2022 and 2021, respectively. Such gains or losses partially offset the foreign currency revaluation changes of the balance sheet items. These foreign currencies revaluation changes are also recognized under financial income, net.

 

Cash Flow Hedging - Hedges of forecasted foreign currency payroll and other operating expenses

As of March 31, 2022, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of $42.0 million into NIS. The Company uses short-term cash flow hedge contracts to reduce its exposure to variability in expected future cash flows resulting mainly from payroll costs and other operating expenses denominated in NIS. The changes in fair value of those contracts are included in the Company’s accumulated other comprehensive loss.

 

Cash Flow Hedging - Hedges of forecasted foreign currency revenue

As of March 31, 2022, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of 41.1 million Euro into U.S. dollars. The Company transacts business in U.S. dollars and in various other currencies. The Company may use foreign exchange or forward contracts to hedge certain cash flow exposures resulting from changes in these foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities of up to twelve months. The Company enters into these foreign exchange contracts to hedge a portion of its forecasted foreign currency denominated revenue in the normal course of business, and, accordingly, they are not speculative in nature.

 

16

 STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

Note 11. Equity

a. Stock-based compensation plans

Stock-based compensation expenses for equity-classified stock options, restricted share units (“RSUs”) and performance-based restricted share units (PSUs) were allocated as follows:

 

  Three Months Ended March 31,
  2022 2021
  U.S $ in thousands
     
Cost of sales $900  $634 
Research and development, net  1,786   1,424 
Selling, general and administrative  5,847   5,147 
Total stock-based compensation expenses $8,533  $7,205 

A summary of the Company’s stock option activity for the three months ended March 31, 2022 is as follows:

 

  Number of OptionsWeighted Average Exercise Price
Options outstanding as of January 1, 2022 $1,732,368 $28.85 
Granted  
-
  
-
 
Exercised  (12,829 12.02 
Forfeited  (13,605 25.11 
Options outstanding as of March 31, 2022  1,705,934  29.01 
Options exercisable as of March 31, 2022 $1,374,696 $32.04 

As of March 31, 2022, the unrecognized compensation cost of $2.1 million related to all unvested, equity-classified stock options is expected to be recognized as an expense over a weighted-average period of 2.7 years.

 

17

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

A summary of the Company’s RSUs and PSUs activity for the three months ended March 31, 2022 is as follows:

 

  Number of RSUs and PSUsWeighted Average Grant Date Fair Value
Unvested as of January 1, 2022 $3,082,798 $26.36 
Granted  1,377,792  22.13 
Vested  (721,316 27.30 
Forfeited  (68,830 26.87 
Unvested as of March 31, 2022 $3,670,444 $24.58 

The fair value of RSUs and PSUs is determined based on the quoted price of the Company’s ordinary shares on the date of the grant.

As of March 31, 2022, the unrecognized compensation cost of $75 million related to all unvested, equity-classified RSUs and PSUs is expected to be recognized as expense over a weighted-average period of 2.7 years.

 

b. Accumulated other comprehensive loss

The following tables present the changes in the components of accumulated other comprehensive income (loss), net of taxes, for the three months ended March 31, 2022 and 2021, respectively:

 

  Three Months Ended March 31, 2022
  Net Unrealized Gain (Loss) on Cash Flow Hedges  Foreign Currency Translation Adjustments  Total
  U.S. $ in thousands
         
Balance as of January 1, 2022 $1,572   $(10,343  $(8,771
Other comprehensive income (loss) before reclassifications  271    (702   (431
Amounts reclassified from accumulated other comprehensive loss  (622   
-
    (622
Other comprehensive income (loss)  (351   (702   (1,053
Balance as of March 31, 2022 $1,221   $(11,045  $(9,824

 

18

STRATASYS LTD.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

 

  Three Months Ended March 31, 2021
  Net Unrealized Gain (Loss) on Cash Flow Hedges  Foreign Currency Translation Adjustments  Total
  U.S. $ in thousands
         
Balance as of January 1, 2021 $(1,673  $(7,173  $(8,846
Other comprehensive income (loss) before reclassifications  1,607    (961   646 
Amounts reclassified from accumulated other comprehensive loss  566    
-
    566 
Other comprehensive income (loss)  2,173    (961   1,212 
Balance as of March 31, 2021 $500   $(8,134  $(7,634

 

c. Public offering of ordinary shares

During March 2021, the Company completed a capital raise of $218.9 million, net of underwriting discounts and offering expenses. The total number of shares sold by the Company in the public offering was 7,931,034.
 
       A deferred tax asset in an amount of $1.2 million was recorded in respect of a tax benefit, arising from the underwriting discounts and offering expenses, as an increase to Additional Paid-In Capital.
 

Note 12. Contingencies

 

 During the fourth quarter of 2021, the Company reached preliminary settlement on an employee-related litigation matter in the US. The financial statements for the period ended March 31, 2022 and the year ended December 31, 2021 include a provision in respect of this settlement.
 
      The Company is a party to various legal proceedings from time to time, the outcome of which, in the opinion of management, will not have a significant effect on the financial position, profitability or cash flows of the Company.
       

 

19

*Includes $22.0 million and $21.1 million under long term deferred revenue in the Company's consolidated balance sheets as of March 31, 2022 and December 31, 2021, respectively. Includes $2.4 million under Accrued expenses and other current liabilities in the Company's consolidated balance sheets as of March 31, 2022 and December 31, 2021. false --12-31 Q1 2022 2022-03-31 0001517396 0001517396 2022-01-01 2022-03-31 0001517396 2022-03-31 0001517396 2021-12-31 0001517396 us-gaap:ProductMember 2022-01-01 2022-03-31 0001517396 us-gaap:ProductMember 2021-01-01 2021-03-31 0001517396 us-gaap:ServiceMember 2022-01-01 2022-03-31 0001517396 us-gaap:ServiceMember 2021-01-01 2021-03-31 0001517396 2021-01-01 2021-03-31 0001517396 us-gaap:CommonStockMember 2021-12-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001517396 us-gaap:RetainedEarningsMember 2021-12-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001517396 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001517396 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001517396 us-gaap:CommonStockMember 2022-03-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001517396 us-gaap:RetainedEarningsMember 2022-03-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001517396 us-gaap:CommonStockMember 2020-12-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001517396 us-gaap:RetainedEarningsMember 2020-12-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001517396 2020-12-31 0001517396 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001517396 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001517396 us-gaap:CommonStockMember 2021-03-31 0001517396 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001517396 us-gaap:RetainedEarningsMember 2021-03-31 0001517396 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001517396 2021-03-31 0001517396 ssys:BusinessCombinationMember 2022-01-01 2022-03-31 0001517396 ssys:XAARMember 2019-10-01 2019-12-31 0001517396 ssys:XAARMember 2022-01-01 2022-03-31 0001517396 ssys:XAARMember 2021-11-01 0001517396 2021-11-01 2021-11-01 0001517396 2021-10-01 2021-12-31 0001517396 2022-02-10 2022-02-16 0001517396 ssys:MakerBotMember 2022-05-01 2022-05-12 0001517396 ssys:MakerBotMember 2022-05-12 0001517396 ssys:NPMCapitalMember 2022-05-01 2022-05-12 0001517396 ssys:NPMCapitalMember 2022-03-31 0001517396 ssys:XAARMember 2022-03-31 0001517396 2021-01-01 2021-12-31 0001517396 ssys:SystemsMember pf0:AmericasMember 2022-01-01 2022-03-31 0001517396 ssys:SystemsMember pf0:AmericasMember 2021-01-01 2021-03-31 0001517396 ssys:ConsumablesMember pf0:AmericasMember 2022-01-01 2022-03-31 0001517396 ssys:ConsumablesMember pf0:AmericasMember 2021-01-01 2021-03-31 0001517396 us-gaap:ServiceMember pf0:AmericasMember 2022-01-01 2022-03-31 0001517396 us-gaap:ServiceMember pf0:AmericasMember 2021-01-01 2021-03-31 0001517396 pf0:AmericasMember 2022-01-01 2022-03-31 0001517396 pf0:AmericasMember 2021-01-01 2021-03-31 0001517396 ssys:SystemsMember us-gaap:EMEAMember 2022-01-01 2022-03-31 0001517396 ssys:SystemsMember us-gaap:EMEAMember 2021-01-01 2021-03-31 0001517396 ssys:ConsumablesMember us-gaap:EMEAMember 2022-01-01 2022-03-31 0001517396 ssys:ConsumablesMember us-gaap:EMEAMember 2021-01-01 2021-03-31 0001517396 us-gaap:ServiceMember us-gaap:EMEAMember 2022-01-01 2022-03-31 0001517396 us-gaap:ServiceMember us-gaap:EMEAMember 2021-01-01 2021-03-31 0001517396 us-gaap:EMEAMember 2022-01-01 2022-03-31 0001517396 us-gaap:EMEAMember 2021-01-01 2021-03-31 0001517396 ssys:SystemsMember pf0:AsiaPacificMember 2022-01-01 2022-03-31 0001517396 ssys:SystemsMember pf0:AsiaPacificMember 2021-01-01 2021-03-31 0001517396 ssys:ConsumablesMember pf0:AsiaPacificMember 2022-01-01 2022-03-31 0001517396 ssys:ConsumablesMember pf0:AsiaPacificMember 2021-01-01 2021-03-31 0001517396 us-gaap:ServiceMember pf0:AsiaPacificMember 2022-01-01 2022-03-31 0001517396 us-gaap:ServiceMember pf0:AsiaPacificMember 2021-01-01 2021-03-31 0001517396 pf0:AsiaPacificMember 2022-01-01 2022-03-31 0001517396 pf0:AsiaPacificMember 2021-01-01 2021-03-31 0001517396 us-gaap:ProductMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-03-31 0001517396 us-gaap:ProductMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-03-31 0001517396 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-03-31 0001517396 us-gaap:ServiceMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-03-31 0001517396 us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-03-31 0001517396 us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-03-31 0001517396 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-03-31 0001517396 us-gaap:ServiceMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-03-31 0001517396 us-gaap:TransferredOverTimeMember 2022-01-01 2022-03-31 0001517396 us-gaap:TransferredOverTimeMember 2021-01-01 2021-03-31 0001517396 us-gaap:GoodwillMember 2021-12-31 0001517396 us-gaap:GoodwillMember 2022-01-01 2022-03-31 0001517396 us-gaap:GoodwillMember 2022-03-31 0001517396 us-gaap:DevelopedTechnologyRightsMember 2022-03-31 0001517396 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0001517396 us-gaap:PatentsMember 2022-03-31 0001517396 us-gaap:PatentsMember 2021-12-31 0001517396 us-gaap:TrademarksAndTradeNamesMember 2022-03-31 0001517396 us-gaap:TrademarksAndTradeNamesMember 2021-12-31 0001517396 us-gaap:CustomerRelationshipsMember 2022-03-31 0001517396 us-gaap:CustomerRelationshipsMember 2021-12-31 0001517396 us-gaap:ComputerSoftwareIntangibleAssetMember 2022-03-31 0001517396 us-gaap:ComputerSoftwareIntangibleAssetMember 2021-12-31 0001517396 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001517396 us-gaap:FairValueInputsLevel3Member 2022-03-31 0001517396 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001517396 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:MeasurementInputConversionPriceMember 2022-03-31 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember ssys:MeasurementInputConversionOfPriceMember 2022-03-31 0001517396 us-gaap:NondesignatedMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2022-03-31 0001517396 us-gaap:NondesignatedMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2021-12-31 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2022-03-31 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2021-12-31 0001517396 us-gaap:NondesignatedMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember 2022-03-31 0001517396 us-gaap:NondesignatedMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember 2021-12-31 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember 2022-03-31 0001517396 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember 2021-12-31 0001517396 us-gaap:EmployeeStockOptionMember 2022-03-31 0001517396 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001517396 ssys:RestrictedAndPhantomShareUnitsMember 2022-03-31 0001517396 ssys:RestrictedAndPhantomShareUnitsMember 2022-01-01 2022-03-31 0001517396 ssys:OrdinarySharesMember 2021-01-01 2021-03-31 0001517396 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001517396 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001517396 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001517396 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001517396 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001517396 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001517396 ssys:StockbasedCompensationPlansMember 2022-01-01 2022-03-31 0001517396 ssys:StockbasedCompensationPlansMember 2021-01-01 2021-03-31 0001517396 ssys:RestrictedAndPhantomShareUnitsMember 2021-12-31 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-03-31 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-03-31 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-03-31 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-03-31 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0001517396 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-03-31 0001517396 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 iso4217:USD iso4217:ILS xbrli:shares xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:ILS iso4217:EUR